Navigation Links
Golimumab Phase 3 Data Show Significant Improvement In Physical Function In Patients with Rheumatoid Arthritis
Date:10/27/2008

participating in the study developed malignancies: one patient taking golimumab 100 mg plus methotrexate developed breast cancer, one patient taking placebo plus methotrexate developed Bowen's disease and squamous cell skin cancer, one patient taking golimumab 100 mg plus placebo developed basal cell cancer, and one patient taking golimumab 100 mg plus placebo developed squamous cell carcinoma. One patient receiving golimumab 100 mg plus placebo died from diarrhea, colitis and sepsis.

Anti-TNF therapies have been associated with serious and sometimes fatal risks including the risk of tuberculosis and other serious infections, malignancies, heart failure, central nervous system disorders, reactivation of hepatitis B and other serious events.

About Rheumatoid Arthritis

RA is a chronic and debilitating disease that affects approximately 1.3 million people in the United States and more than three million people in Europe. Signs and symptoms of RA include pain, stiffness and motion restriction in multiple joints. Because RA is a progressive disease, it can cause permanent joint deformity and severe disability if not diagnosed early or if initial treatment is delayed. RA can occur at any age, but is most common in adults 30-50 years old and is two-to-three times more prevalent in women than in men. The cause of RA is unknown, although genetic factors may contribute to the disease.

About Golimumab

Golimumab, the next-generation human anti-TNF-alpha monoclonal antibody from Centocor Inc. and Schering-Plough Corporation, is currently in the most comprehensive Phase 3 development program to date for an anti-TNF-alpha biologic therapy. With ongoing studies for the treatment of RA, including a study in a methotrexate-naive patient population, psoriatic arthritis and ankylosing spondylitis, golimumab is being studied as an every four-week subcutaneous injection and an intravenous (IV) infusion therapy. Golimumab targets and neutralizes both th
'/>"/>

SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
2. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
4. One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
8. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
9. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
10. Phase III Trial Finds Pharmaxis Bronchitol Effective
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 18, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced ... Materials - Global Strategic Business Report" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the ... US$ Million by the following Product ...
(Date:9/18/2014)... -- Research and Markets has announced the ... Industry Report, 2014-2017" report to their offering. ... can differentiate into specialized cells and can divide (through ... can be applied to treatment of cardiovascular diseases, leukemia ... damage or lesion of liver, kidney and other parenchymal ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, ... report to their offering. The global ... CAGR of 22.7% from 2014 to 2019. Factors such ... growing adoption of companion diagnostics by the pharmaceutical industry, ...
(Date:9/18/2014)... , Sept. 18, 2014  MEI Pharma, Inc. (Nasdaq: ... clinical development of novel therapies for cancer, announced today that ... Officer, will present at BioCentury,s NewsMakers in the Biotech ... a.m. Eastern time from the Millennium Broadway Hotel & Conference ... webcast of the presentation can be accessed at www.meipharma.com ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3
... consulting firm ,based in Draper, UT, named Epic Systems ... Report Card. The study, which included 200 vendors, was ... and clinicians representing over 4,000 healthcare facilities. , ,KLAS ... information technology (HIT) vendors and releases its Top 20 ...
... game makers , ,Eau Claire, WI-- Silicon ... Graphics of Wilsonville, Ore., to offer improved custom ... spectrum. , ,The business collaboration is meant to speed ... additional manufacturing operations due to undetected errors in very ...
... intranet infrastructure helped Cisco Systems - the ... explosive growth in the late '80s ad early '90s. ... has come from careful expansion of the company's product ... Marquette University Business Leaders Forum Breakfast. , ...
Cached Biology Technology:Silicon Logic Teams Up to Save Money 2Cisco Chairman Praises University Research 2Cisco Chairman Praises University Research 3
(Date:9/18/2014)... be cheerful, happy-go-lucky characters, so you might expect that ... , In fact some dogs are distinctly more pessimistic ... , "This research is exciting because it measures ... non-invasively. It offers researchers and dog owners an insight ... said Dr Melissa Starling, from the Faculty of Veterinary ...
(Date:9/18/2014)... it that when people are too stressed they are ... the Brain Mind Institute (BMI) at EPFL have just ... between chronic stress and the loss of social skills ... attacks a synaptic regulatory molecule in the brain. This ... Communications . , Carmen Sandi,s team went to ...
(Date:9/17/2014)... health care to reproductive technologies, the justice and ... of people to identify key issues, articulate their ... find the most defensible ways forward. But what ... societal conversations?, The Hastings Center and the Presidential ... teamed up to publish a series of essays ...
Breaking Biology News(10 mins):Dogs can be pessimists too 2Dogs can be pessimists too 3How stress tears us apart 2Why bioethics literacy matters 2Why bioethics literacy matters 3
... Now, researchers at Yonsei University in Seoul, Republic of ... a layer of silver ions that can prevent growth ... Salmonella typhimurium and Campylobacter jejuni . The ... be particularly useful for applications in disaster recovery and ...
... is killing fishers in the southern Sierra Nevada, according ... scientists from the U.S. Forest Service,s Pacific Southwest Research ... Berkeley, and the Integral Ecology Research Center. ... team documented that rodenticides were being found in the ...
... 27, 2013 /PRNewswire-iReach/ -- Industry leader in healthcare ... to improve the family waiting room experience.  While ... the company now offers a customizable multilingual whiteboard ... preference.  Over 3o languages are currently available, with ...
Cached Biology News:Spinning up antibacterial silver on glass 2Illegal marijuana grows threaten fishers in the southern Sierra Nevada 2PatientStream announces the industry's first Multilingual family waiting room board 2PatientStream announces the industry's first Multilingual family waiting room board 3
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
... Recognizes K+ Cl- Cotransporter-1 ... no significant sequence homology ... CCC.,SPECIES REACTIVITIES: The immunogen ... in human, mouse, porcine ...
IEX-1 S/L (H-20)...
Mouse monoclonal [1.T.4] to WAVE 1 ( Abpromise for all tested applications). Antigen: His6 fusion protein corresponding to full-length rat WAVE1. Entrez Gene ID: 8936...
Biology Products: